<DOC>
	<DOC>NCT02008448</DOC>
	<brief_summary>The investigators have conducted a prospective, double-blind, randomized study to assess the comparative safety and efficacy of two different ablation strategies, PVI plus linear lesions (LL) plus botulinum toxin injection versus PVI plus linear lesions (LL), in patients with persistent or longstanding persistent AF. Results were assessed with the use of an implanted monitoring device (IMD).</brief_summary>
	<brief_title>Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Persistent and longstanding persistent AF congestive heart failure LV ejection fraction &lt; 35% left atrial diameter &gt; 60 mm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>